SWOG Institutional Grant

描述（由申请人提供）：H. Lee Moffitt癌症中心定位独特，准备追求其治疗和预防癌症的使命。H. Lee Moffitt癌症中心由佛罗里达州立法机构于20世纪80年代成立，旨在成为一个全州范围的研究机构，并为基础和临床研究以及患者治疗的多学科方法提供国家资源，是NCI唯一指定的佛罗里达州综合癌症中心。患者基础广泛。ECOG的科学领导地位正在增长，有81名研究人员，其中许多人正在莫菲特进行研究人员发起的试验。癌症中心对ECOG的承诺是坚定的。1992年在John Ruckdeschel博士的领导下作为附属机构开始，它很快就获得了主要成员地位，然后获得了自己的U-10资助。威廉·道尔顿医生成为h·李·莫菲特癌症中心的新任首席执行官。他对合作小组机制作为研究者发起的试验的一个出口有着深刻的承诺。癌症中心通过14个多学科项目运作。每个项目负责人都由道尔顿博士负责制定一项战略计划其中包括对所有疾病级别的临床试验。这将增加临床试验的收益。ECOG项目包括首席研究员Julie a . Kish（医学博士）、协调员Stephanie Daniels（注册会计师）、数据经理Michele Stungis（注册会计师）和一个秘书职位，已成为该机构临床试验行为的典范。这延伸到Moffitt的大型附属网络，ECOG的政策和程序指导认证，监督和教育。道尔顿博士发起了一项旨在增加少数族裔参与临床试验的主要倡议，名为解决多样性问题特别工作组（Taskforce for Addressing Diversity， TAD）。因此，H. Lee Moffitt癌症中心ECOG项目的目标是增加总体和少数群体的累积，并教育和指导研究人员在他们的研究人员发起的试验中利用合作小组。

DESCRIPTION (provided by applicant): The H. Lee Moffitt Cancer Center is uniquely positioned and prepared to pursue its mission of curing and preventing cancer. Founded by the Florida Legislature in the 1980's to become a statewide research institute and a national resource for basic and clinical research and multidisciplinary approach to patient treatment, the H. Lee Moffitt Cancer Center is the only NCI designated Comprehensive Cancer Center based in the state of Florida. The patient base is broad. The scientific leadership is growing with 81 investigators in ECOG, many of whom are doing investigator-initiated trials at Moffitt. The Cancer Center's commitment to ECOG is strong. Starting as an affiliate in 1992 under Dr. John Ruckdeschel, it soon achieved main member status and then received its own U-10 funding. Dr. William Dalton has become the new CEO of H. Lee Moffitt Cancer Center. He has a deep commitment to the cooperative group mechanism as an outlet for investigator initiated trials. The Cancer Center functions through 14 multidisciplinary programs. Each program leader has been charged by Dr. Dalton to develop a strategic plan which includes clinical trials at all levels of disease. This should enhance accrual to clinical trials. The ECOG program which includes the Principal Investigator, Julie A. Kish, MD, Coordinator, Stephanie Daniels, RN, Data Manager, Michele Stungis, and a 0.5 secretarial position, has become a model for clinical trial conduct for the institution. This extended to Moffitt's large affiliate network, where ECOG policies and procedures guide credentialing, monitoring and education. A major initiative to increase accrual of minorities to clinical trials has been instituted by Dr. Dalton called the Taskforce for Addressing Diversity (TAD). Thus, the goals of the ECOG Program at H. Lee Moffitt Cancer Center are to increase overall and minority accrual, and educate and mentor investigators to utilize the cooperative group for their investigator-initiated trials.